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Abstract  26 
We previously reported the Bruton’s tyrosine kinase (BTK) inhibitors ibrutinib and 27 
acalabrutinib improve outcomes in a mouse model of polymicrobial sepsis. Now we show that 28 
genetic deficiency of the BTK gene alone in Xid mice confers protection against cardiac, renal 29 
and liver injury in polymicrobial sepsis and reduces hyperimmune stimulation (‘cytokine 30 
storm’) induced by an overwhelming bacterial infection. Protection is due in part to enhanced 31 
bacterial phagocytosis in vivo, changes in lipid metabolism and decreased activation of NF-kB 32 
and the NLRP3 inflammasome. The inactivation of BTK leads to reduced innate immune cell 33 
recruitment and a phenotypic switch from M1 to M2 macrophages, aiding in the resolution of 34 
sepsis. We have also found that BTK expression in humans is increased in the blood of septic 35 
non-survivors, while lower expression is associated with survival from sepsis. Importantly no 36 
further reduction in organ damage, cytokine production or changes in plasma metabolites is 37 
seen in Xid mice treated with the BTK inhibitor ibrutinib, demonstrating that the protective 38 
effects of BTK inhibitors in polymicrobial sepsis are mediated solely by inhibition of BTK and 39 
not by off-target effects of this class of drugs. 40 
 41 
Introduction  42 
Sepsis is a common and life-threatening condition caused by a dysregulated host response to 43 
an infection, either bacterial, fungal or viral (1). Sepsis is a major public health problem leading 44 
to multiple organ dysfunction and death. Globally there are 50 million cases of sepsis resulting 45 
in the death of 11 million people every year representing 20% of all deaths worldwide (2). 46 
Despite intensive, supportive care and current treatments (antibiotic therapy and fluid 47 
resuscitation), no targeted therapies have proven effective at reducing mortality (3,4). There is 48 
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an urgent need for the development of pharmacological treatments for sepsis-induced organ 49 
dysfunction (5). 50 
 51 
Bruton’s tyrosine kinase (BTK) is well known as a critical component of the B-cell antigen 52 
receptor (BCR) signalling pathway (6). BTK is also involved in the activation of the toll-like 53 
receptor (TLR) signalling pathways (by binding to the TIR domain of TLR4 and TLR’s adaptor 54 
molecules MyD88, and Mal) and the NLRP3 inflammasome (by binding to the ASC 55 
component) (7–9). Activation of both the TLR signalling pathway and the NLRP3 56 
inflammasome play a pivotal role in the pathophysiology of sepsis (10,11). The expression of 57 
BTK is not restricted to B cells, as BTK is also expressed in cells of myeloid lineage, including 58 
macrophages and neutrophils (12,13), activation of which contributes to the pathophysiology 59 
of sepsis.  60 
 61 
We have recently shown that the BTK inhibitors ibrutinib (first generation) and acalabrutinib 62 
(more selective, second generation) attenuate the systemic inflammation (‘cytokine storm’) and 63 
the multiple organ failure caused by sepsis in mice (14). Ibrutinib is already approved for the 64 
use in chronic lymphatic leukaemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, 65 
and graft vs. host disease (15) and acalabrutinib in mantle cell lymphoma (16). The recent 66 
COVID-19 pandemic has driven the search for drugs that can be repurposed to either reduce 67 
virus load and/or the cytokine storm in patients with severe COVID-19 infections. It has been 68 
found that BTK activation and IL-6 production is increased in COVID-19 patients and the 69 
effects of acalabrutinib are currently being evaluated in these patients (17). Roschewski et al. 70 
showed that some severe COVID-19 patients receiving acalabrutinib had improved 71 
oxygenation and reduced CRP and plasma IL-6, suggesting that BTK inhibitors could be 72 
repurposed for diseases involving excessive inflammation.  73 
 74 
Although we have proposed that the inhibition of BTK is the key driver of the observed 75 
beneficial effects of BTK inhibitors in sepsis, it is possible that some of the well-known off-76 
target effects of these compounds account for or, at least, contribute to the beneficial effects 77 
observed (14). For instance, we identified that both ibrutinib and acalabrutinib strongly inhibit 78 
five different kinases: BTK, Bmx, ErbB4, RIPK2, and TEC. Our discovery that acalabrutinib 79 
and ibrutinib reduce inflammation and organ dysfunction in sepsis has triggered three 80 
important questions: (1) Does inhibition of BTK activity alone account for the observed 81 
beneficial effects? And (2) Does inhibition of systemic inflammation reduce the host response 82 
to infection and ultimately cause increased harm? (3) What effect does BTK inactivation have 83 
on the metabolomic profile of septic mice?  Interest in metabolomic profiling is growing, as 84 
the metabolome is the result of expression and function of a multitude of proteins and, hence, 85 
has been suggested to be a sensitive readout of drug responses (18,19). The present study was 86 
designed to address these questions by inducing polymicrobial sepsis in mice with X-linked 87 
immunodeficiency (Xid). Xid mice have a missense mutation within the BTK gene (arginine to 88 
cysteine at position 28 (R28C)) in the N-terminally located pleckstrin homology domain, 89 
resulting in expression of a BTK protein that is functionally inactive (20,21). Having developed 90 
a model of sepsis in Xid mice (and wild-type mice, CBA background), we have investigated 91 
the impact of impaired BTK function on organ dysfunction, systemic inflammation (cytokine 92 
storm), changes in plasma metabolites, and bacterial clearance. 93 
 94 
Methods  95 
Ethical statement  96 
The Animal Welfare Ethics Review Boards of Queen Mary University of London and The 97 
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Dunn School of Pathology in the University of Oxford approved all experiments in accordance 98 
with the Home Office guidance on the operation of Animals (Scientific Procedures Act 1986) 99 
published by Her Majesty’s Stationery Office and the Guide for the Care and Use of Laboratory 100 
Animals of the National Research Council. Work was conducted under U.K. Home Office 101 
project licence number PCF29685 and P144E44F2.  102 
 103 
Mice  104 
This study was carried out on twenty-three 10-week-old, male CBA mice (Charles River 105 
Laboratories UK Ltd., Kent, UK) and twenty-one 10-week-old, male CBA/CaHN-Btkxid/J (Xid) 106 
mice (from Jackson laboratory), weighing 25–30 g and kept under standard laboratory 107 
conditions. Six mice were housed together (in each cage) with access to a chow diet and 108 
water ad libitum. They were subjected to a 12-h light and dark cycle with a temperature 109 
maintained at 19–23°C. Group sizes for each experiment were calculated following power 110 
calculations based on previous studies (14). 111 
 112 
Polymicrobial sepsis  113 
Cecal ligation and puncture (CLP) was performed in 10-week-old male CBA (wild type) or 114 
Xid mice as previously described (14,22). Mice were randomly assigned to undergo CLP or 115 
sham-operated surgery, the surgeon was blinded to the genotype of the mouse. Briefly, mice 116 
were anesthetised with isoflurane (2% delivered in O2) and the cecum was fully ligated below 117 
the ileocecal valve. A double puncture was made with a 18G needle into the cecum and a small 118 
amount of faeces was squeezed out after which the cecum was returned to its anatomical 119 
position, then the laparotomy was closed. All animals received fluids (5 ml/kg saline into 120 
abdomen before closure and 10 ml/kg saline s.c., immediately after surgery), antibiotics 121 
(Imipenem/Cilastatin; 20 mg/kg body weight s.c.), and analgesics (buprenorphine; 0.05 mg/kg 122 
body weight i.p.) at 6 h and 18 h after surgery. Sham-operated mice underwent the same 123 
procedure, but without CLP. At 1 h after CLP, WT or Xid mice received 30 mg/kg ibrutinib 124 
(Selleck Chemicals) intravenously.  125 
 126 
A clinical score for monitoring the health of experimental mice was used to evaluate the 127 
symptoms consistent with murine sepsis. The maximum score of 6 comprised the presence of 128 
the following signs: lethargy, piloerection, tremors, periorbital exudates, respiratory distress, 129 
and diarrhoea. Mice with a clinical score >3 were defined as exhibiting severe sepsis, against 130 
a moderate sepsis for a score ≤3. Animals were culled at 24 h after the onset of sepsis (CLP).   131 
 132 
Assessment of cardiac function in vivo 133 
At 24 h post CLP, mice were anesthetised (0.5 - 2% isoflurane in O2); body temperature was 134 
maintained at 37oC and heart rate was maintained at 450 bpm. Then, cardiac function was 135 
assessed by M-mode and B-mode echocardiography using the VisualSonics Vevo 3100 136 
echocardiographic system and a MX550D transducer. The following parameters were 137 
measured: left ventricular ejection fraction, fractional shortening, fractional area change, 138 
cardiac output, stroke volume and myocardial performance index, as described previously (14).  139 
 140 
Kidney dysfunction and hepatocellular injury  141 
After 24 h, mice were sacrificed by terminal cardiac puncture, where terminal blood samples 142 
were immediately decanted into 1.3 ml serum gel tubes (Sarstedt, Nürnbrecht, Germany). 143 
Blood was allowed to coagulate for at least 10 min at room temperature, then samples were 144 
centrifuged at 9000 rpm for 3 min to separate the serum.  Then 100 µl of serum was snap frozen 145 
in liquid nitrogen and sent to an independent veterinary testing laboratory (MRC Harwell 146 
Institute, Oxford, UK) to evaluate the following biomarkers in a blinded fashion: Urea and 147 
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creatinine (as markers of renal dysfunction), alanine aminotransferase (ALT), aspartate 148 
transaminase (AST) (markers of hepatocellular injury) and lactate dehydrogenase (LDH) 149 
(marker of cell injury).  150 
 151 
Quantification of immune cells after peritoneal lavage  152 
Peritoneal lavage exudate was collected by injecting 5 ml of 2 mM of EDTA in PBS into the 153 
peritoneal cavity. After gentle massaging, approximately 4ml of exudate was removed with an 154 
18G needle. Cells were washed in FACS buffer (0.05 % BSA, 2 mM EDTA in PBS pH 7.4) 155 
and then blocked using anti-CD16/32 (Biolegend) for 10 min at 4oC. Peritoneal cells were 156 
analysed using anti-CD45 (clone 30-F11; BioLegend), anti-CD11b (clone M1/70; BioLegend), 157 
anti-F4/80 (clone BM8; BioLegend), anti-Ly6G (clone 1A8; BioLegend), anti-CD206 (clone 158 
C068C2; BioLegend), and anti-MHCII (clone. M5/114.15.2; BioLegend) antibodies. Absolute 159 
cell count was calculated by the addition of counting beads (BioLegend). Data were acquired 160 
using BD LSR II Fortessa (Becton Dickinson) and analysed using FlowJo analysis software 161 
(version 10.6, Treestar Inc.). The gating strategy is depicted in supplementary Figure S1.  162 
 163 
Cytokine analysis 164 
The principle of multiplex flow immunoassay technology has been reviewed previously 165 
(23,24). Cytokines, chemokines and a growth factor were determined in serum by Bio-Plex Pro 166 
Mouse Chemokine 31-Plex panel assay (Bio-Rad, Kabelsketal, Germany). The cytokines IL-167 
1ß, −2, −4, −6, −10, −16, CCL1, −2, −3, −4, −5, −7, −11, −12, −17, −19, −20, −22, −24, −27, 168 
IFN-γ, TNF-α and the chemokines CX3CL1, CXCL1, −2, −5, −10, −11, −12 ,−13, −16 and 169 
the growth factor GM-CSF were measured according to the manufacturer's instructions. 170 
Bacteria counting  171 
Accurate evaluation of the number of bacteria in peritoneal lavage fluid and blood samples was 172 
performed by flow cytometry using the SYTO BC bacteria counting kit (Thermo Fischer 173 
Scientific).  174 
Phagocytic ability 175 
Peritoneal lavage exudate containing neutrophils and macrophages was obtained 24 h after 176 
CLP as described above. pHrodoTM  red E.Coli bioparticlesTM (Thermo Fischer Scientific) were 177 
resuspended in live cell imagining solution (BioLegend) at 10 mg/ml  and 10  µL of bioparticles 178 
were opsonised with 20 µL of fresh serum for 1h at 37oC under gentle agitation, after which 179 
they were washed and resuspended in 10 µL of live cell imagining solution. 1 × 106 cells of 180 
peritoneal exudate were collected by centrifugation (300 g x 5 min) and resuspended in 890 181 
µL of live cell imaging solution, after which 100 µl of fresh serum and 10 µL of optimised 182 
bioparticles were added and incubated for 45 min at 37oC under gentle agitation in the dark. 183 
Cells were washed and then blocked using anti-CD16/32 (Biolegend) for 10 min at 4oC 184 
followed by staining with surface markers anti-CD11b (clone M1/70; BioLegend), anti-Ly6G 185 
(clone 1A8; BioLegend) and anti-F4/80 (clone BM8; BioLegend) for 30 min at 4oC. 10,000 186 
CD11b+ cells were collected by Amnis® ImageStream®X Mk II Imaging Flow Cytometer 187 
(Luminex) at a magnification of x40 and analysed by IDEAS software for each experimental 188 
sample. Neutrophils were identified as (CD11b+, Ly6G+, F4/80-) and macrophages were 189 
identified as (CD11b+, Ly6G-, F4/80+). This equated to approximately 7000 neutrophils and 190 
2000 macrophages for both WT and Xid mice to undergo phagocytosis analysis via IDEAS 191 
software. For WT mice the average number of cells positive with pHrodo E.coli BioParticles 192 
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were 4200 neutrophils and 1,200 macrophages. For Xid mice the average number of cells 193 
positive with pHrodo E.coli BioParticles were neutrophils 5,600 and 1,200 macrophages. 194 
Western blots  195 
Immunoblot analyses of cardiac tissue samples were carried out using a semi-quantitative 196 
western blotting analysis. The antibody used were: 1:1,000 rabbit anti-Ser176/180-IKKα/β, 197 
1:1,000 rabbit anti-total IKKα/β, mouse anti-Ser32/36-IκBα, mouse anti-total IκBα, rabbit anti-198 
Tyr223-BTK, rabbit anti-total BTK, rabbit anti-Tyr1217 PLCγ, rabbit anti-total PLCγ (from Cell 199 
Signaling), 1:5,000 rabbit anti NLRP3 inflammasome (from Abcam), mouse anti-caspase 1 200 
(p20) (from Adipogen). The apex of the heart was taken and homogenized. Proteins were then 201 
extracted as previously described (25) and concentrations were quantified by bicinchoninic 202 
acid (BCA) protein assay (Thermo Fisher Scientific Rockford, IL). Proteins were separated by 203 
8% sodium dodecyl sulfate (SDS)-PAGE and transferred to polyvinylidene fluoride 204 
membranes. Membranes were blocked in 10% milk solution with TBS-Tween and then 205 
incubated with the primary antibody overnight at 4°C. The next day the secondary antibody 206 
was added for 30 min at room temperature and visualized using the ECL detection system. 207 
Tubulin was used as loading control. The immunoreactive bands were analyzed by the Bio-208 
Rad Image Lab Software™ 6.0.1 and results were normalised to the sham bands. 209 
 210 
BTK gene expression in whole human blood 211 
Original data was obtained from the gene expression omnibus under dataset number GDS4971 212 
which was published by Parnell GP et al. (26). RNA isolated from whole-blood samples of 213 
survivors (n = 26) and non-survivors (n = 9) of sepsis as well as healthy participants (n = 18) 214 
over the course of 5 days was assayed on the Illumina HT-12 gene expression microarray 215 
consisting of 48,804 probes. The dataset was analysed for expression of BTK gene in these 216 
three groups. The figure was generated using R software (ver 4.0.2), gene expression is quantile 217 
normalization and log transformation of the data was applied. Significance was determined by 218 
a one-way ANOVA followed by a Bonferroni post hoc test.  219 
 220 
Metabolomic analysis 221 
Metabolites were analyzed by liquid chromatography coupled to triple quadrupole mass 222 
spectrometry (LC-MS/MS) using an ultra-high-performance liquid chromatography (UHPLC) 223 
system (Nexera LC-40 series) and the triple quadrupole mass spectrometer LCMS-8050, both 224 
from Shimadzu Deutschland GmbH (Duisburg, Germany). Samples were analyzed with a 225 
method for sphingosine-1-phosphate and sphingosine and the supplied method packages 226 
“primary metabolites”, “phospholipids” and “lipid mediators” according to the manufacturer’s 227 
protocols (Shimadzu Deutschland GmbH, Duisburg, Germany) with the following 228 
modifications: Twenty microliters of serum sample were precipitated by addition of 200 µL of 229 
methanol (LCMS-grade) in vials. Prior to processing, the methanol was spiked with internal 230 
standard (IS) solution in a final concentration of 45.45 nM. The supernatant was taken for 231 
analysis after 4 days of incubation at -80°C and subsequent centrifugation at 14,000 rcf for 10 232 
min at 4 °C. Primary metabolites were analyzed using the HPLC Column Discovery® HS F5, 233 
3 µm, 150 mm x 2.1 mm from Sigma-Aldrich Chemie GmbH (Munich, Germany). For 234 
phospholipids and lipid mediators, the 2.1 x 150 mm 2.6 µm particle size C8 Kinetex LC 235 
Column (Phenomenex Inc., Torrance, USA) was used. Sphingosine-1-phosphate and 236 
sphingosine were separated using a MultoHigh 100 RP 18-3µ 60 x 2 mm column 237 
(Chromatographie Service GmbH, Langerwehe, Germany) with intermittent runs for 238 
equilibration. Mass spectrometric detection was performed by multiple reactions monitoring 239 
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(MRM) after injection of 10 µl sample, unless stated otherwise. Further information on HPLC 240 
programs and solvents (Table S1), LCMS-8050 settings (Table S2), and recorded mass 241 
transitions of identified significantly changed analytes (Table S3-6) are listed in the 242 
Supplement. Metabolome primary data were analyzed and further processed with LabSolutions 243 
5.91 and LabSolutions Insight 3.10 (Shimadzu Deutschland GmbH, Duisburg, Germany). 244 
Statistics 245 
Statistical differences were determined using a one-way ANOVA, followed by Bonferroni post 246 
hoc test or unpaired Student’s t-test as appropriate (GraphPad Prism 8.0; significant when P < 247 
0.05). Results are expressed as mean ± SEM of three independent experiments. 248 
 249 
Metabolome data were determined by calculating area ratios for each analyte by dividing peak 250 
area of each analyte by peak area of the related IS. Data analysis for metabolome data was 251 
performed as follows: Readings below detection level were set to half of detection level for 252 
each analyte separately. Metabolome data was log2 transformed and normalized by subtracting 253 
median metabolite abundance per sample from all abundances of each sample. Normalization 254 
was carried out separately for primary metabolites, phospholipids and lipid mediators. Z scores 255 
were calculated using mean and standard deviation of all samples. Contrasts were analyzed 256 
pairwise between selected sample groups by unpaired t tests. P-values were Benjamini 257 
Hochberg adjusted (27)  and log2 fold changes were reported (Supplementary Data). Analytes 258 
with adjusted P-values below 0.05 were considered significantly different. For a first 259 
exploratory overview a principal component analysis (PCA) was carried out using the 260 
normalised and scaled metabolome data. Data analysis was carried out using R version 3.4.4 261 
(R Core Team 2018). 262 
 263 
  264 
Results  265 
 266 
Xid mice have 100% predicted survival rate  267 
When compared to sham-operated mice, WT mice subjected to cecal ligation and puncture 268 
(CLP) showed clinical signs of severe sepsis (80%; score >3). In contrast, all Xid mice 269 
subjected to CLP had a score of ≤3 indicating only moderate sepsis (Figure 1A). All mice in 270 
the WT-CLP group which received ibrutinib had a score of ≤3 indicating moderate sepsis and 271 
all mice in the Xid-CLP + ibrutinib group had a score ≤3. When compared to sham-operated 272 
mice, WT mice subjected to CLP experienced hypothermia (a rectal temperature of <30oC) at 273 
24 h after the onset of CLP, whereas the rectal temperature of Xid-CLP, WT-CLP + ibrutinib 274 
and Xid-CLP + ibrutinib remained at 37oC (Figure 1B). A reduction in temperature to <30oC 275 
or a change of 5oC over time in each animal has been reported to predict death in mice with 276 
CLP (28). As mortality of animals is not an acceptable routine endpoint in the UK, we used the 277 
reduction in rectal temperature <30oC as a surrogate marker for mortality. Using this surrogate 278 
marker, we would predict the mortality of WT-CLP mice to be 90% (confirming that our model 279 
is a model of severe sepsis), while the predicted mortality of Xid-CLP mice would be 0% (e.g. 280 
100% predicted survival; Figure 1C). WT mice receiving ibrutinib had a predicted mortality of 281 
15%, whereas Xid-CLP mice receiving ibrutinib had a predicted mortality of 0%. When 282 
compared to sham-operated, WT mice subjected to CLP showed a decrease in heart rate, 283 
whereas the heart rate of Xid-CLP remained similar to that of sham-operated animals (Figure 284 
1D). When compared to WT-CLP mice, the administration of ibrutinib 1 h after CLP attenuated 285 
the decline in heart rate in WT mice. Mice in the Xid-CLP + ibrutinib group had a similar heart 286 
rate to mice in the Xid-CLP group. Xid-CLP mice receiving ibrutinib had a higher heart rate 287 
than WT-CLP mice treated with ibrutinib. 288 
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 289 
Xid mice are protected from sepsis-induced cardiac dysfunction 290 
Cardiac function was assessed in vivo by echocardiography. Figure 1E shows representative 291 
M-mode images in the short axis in sham-operated mice, CLP mice and CLP + ibrutinib mice 292 
of both genotypes. When compared to sham-operated, WT mice subjected to CLP showed a 293 
reduction in ejection fraction (EF), fractional shortening (FS), fractional area change (FAC), 294 
cardiac output (CO), stroke volume (SV) and an increase in myocardial performance index 295 
(MPI), indicating severe global, systolic cardiac dysfunction. In contrast, Xid mice subjected 296 
to CLP had only a very minor cardiac dysfunction and all indices of cardiac performance (EF, 297 
FS, FAC, CO, SV and MPI) were significantly improved from those measured in WT-CLP 298 
(Figure 1 F-K). Thus, the degree of cardiac dysfunction caused by CLP in Xid mice is 299 
significantly reduced when compared to that observed in WT-mice. When compared to WT-300 
CLP mice (CBA background) treatment of WT-mice with ibrutinib 1 h after CLP attenuated 301 
the sepsis-induced cardiac dysfunction. In contrast, administration of ibrutinib to Xid-CLP 302 
mice had no effect on cardiac function (Figure1 F-K), indicating that the addition of ibrutinib 303 
in Xid mice with CLP results in no beneficial or deleterious effects due to off target actions of 304 
the drug.  305 
Xid mice are protected from sepsis-induced kidney dysfunction and hepatocellular injury  306 
Kidney dysfunction and hepatocellular injury was assessed by measuring serum creatinine, 307 
urea, ALT, AST and LDH. When compared to sham-operated mice, WT mice subjected to 308 
CLP had significant renal dysfunction (rise in urea and creatinine), hepatocellular injury (rise 309 
in ALT and AST) and cell injury (rise in LDH). In contrast, in Xid mice subjected to CLP, the 310 
degree of kidney dysfunction, hepatocellular injury and cell injury was significantly reduced 311 
when compared to WT-CLP mice (Figure 1 L-P). When compared to WT-CLP, treatment of 312 
WT-CLP mice with ibrutinib (1 h after CLP) significantly attenuated the rise of plasma/serum 313 
urea, creatinine, ALT, AST and LDH. In contrast, administration of ibrutinib in Xid-CLP mice 314 
had no significant effect on organ dysfunction (as this was prevented in Xid-mice). No 315 
significant difference was observed between WT-CLP + ibrutinib and Xid-CLP + ibrutinib for 316 
any of the parameters of organ dysfunction measured.  317 
 318 
Xid mice do not present with systemic inflammation after polymicrobial sepsis 319 
Using a multiplex array, we analysed 31 cytokines and chemokines in the serum of all animals. 320 
When compared to sham-operated mice, WT mice subjected to CLP sepsis showed a 321 
significant increase in the serum levels of pro-inflammatory cytokines TNF-a, IL-6 and IL-1b, 322 
the anti-inflammatory cytokine IL-10, neutrophils chemoattractant chemokines (KC & ENA-323 
78), monocyte chemoattractant chemokines (MCP-1, MIP-1a and MIP-1b) and G-CSF. In 324 
contrast, the levels of these cytokines and chemokines in the serum of Xid-CLP were 325 
significantly reduced when compared to WT-CLP mice (Figure 2 A-J). When compared to 326 
WT-CLP, treatment of WT-CLP mice with ibrutinib (1 h after CLP) significantly attenuated 327 
the rise in cytokines and chemokines. In contrast, administration of ibrutinib in Xid-CLP-mice 328 
had no significant effect on the production of cytokines and chemokines (as this was prevented 329 
in Xid-mice). No significant difference was observed between WT-CLP + ibrutinib and Xid-330 
CLP + ibrutinib for any cytokines and chemokines. The alterations of a further 21 cytokines 331 
and chemokines can be seen in Figure 2K and absolute values in supplementary Table 7.  332 
Xid mice have fewer infiltrating immune cells in the peritoneum and enhanced 333 
polarisation to M2 macrophages in sepsis 334 
We also evaluated the cell composition and phenotype in the peritoneal exudates of all animals 335 
by flow cytometry gating strategy seen in supplementary Figure 1. When compared to sham-336 
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operated mice, WT mice subjected to CLP showed a significant increase in neutrophils and 337 
macrophages into the peritoneum. In contrast, Xid-CLP mice exhibited a significant reduction 338 
in the number of infiltrating neutrophils and macrophages when compared to WT-CLP mice 339 
(Figure 3A-C). Upon further analysis of the subsets of macrophages, we found that the 340 
macrophages obtained from WT-CLP mice are predominately of the pro-inflammatory M1 341 
phenotype (60% M1 and 40% M2), while the macrophages of Xid-CLP are of the pro-resolving 342 
(anti-inflammatory) M2 phenotype (40% M1 and 60% M2) (Figure 3D-E).  343 
Xid mice have fewer bacteria in peritoneum and blood due to increased phagocytosis in 344 
sepsis 345 
In order to determine the mechanism that accounts for the improved outcome of BTK deficient 346 
mice, we investigated bacterial clearance in vivo in WT and Xid-mice at 24 h after the onset of 347 
CLP, as the survival of sepsis is dependent on the ability to clear bacteria. When compared to 348 
sham-operated mice, WT mice subjected to CLP exhibited elevated peritoneal and blood 349 
bacteria counts (Figure 4A-D). However, Xid-CLP mice had significantly fewer bacteria in the 350 
peritoneal cavity and blood than WT-CLP mice, showing that Xid-mice clear bacteria more 351 
efficiently than WT mice.  352 
 353 
Clearance of bacteria is secondary to phagocytosis of bacteria in neutrophils and macrophages. 354 
Xid mice subjected to CLP presented with a reduced number of infiltrating immune cells, but 355 
also reduced bacterial counts at 24 h post CLP. This raises the question as to how fewer 356 
infiltrating immune cells are able to clear more bacteria? To address this question, we 357 
investigated whether Xid neutrophils and macrophages have increased phagocytic ability in 358 
vivo. We found that the percentage of neutrophils and macrophages, which are phagocytosing 359 
bacteria, are similar in WT-CLP and Xid-CLP mice. However, neutrophils and macrophages 360 
of Xid-CLP mice contain more bacteria per immune cell than WT-CLP mice, showing a 100% 361 
increase in phagocytic ability of both neutrophils and macrophages (Figure 4E-L). 362 
Collectively, this data clearly demonstrates that Xid mice with a deficiency in BTK show 363 
enhanced phagocytosis in vivo resulting in improved clearance of bacteria during a septic 364 
episode. 365 
 366 
BTK, NF-kB and NLRP3 inflammasome are not activated in Xid mice after polymicrobial 367 
sepsis  368 
To understand the signalling mechanism associated with the observed cardiac dysfunction in 369 
CLP-sepsis, we investigated the effect of BTK deficiency in Xid mice on the activation of key 370 
signalling pathways of inflammation: BTK, NF-kB and NLRP3 inflammasome activation 371 
(Figure 5). When compared to sham-operated, WT mice subjected to CLP showed an increase 372 
of BTK activation as demonstrated by significant increases in the phosphorylation of cardiac 373 
BTK at Tyr223 and the phosphorylation of PLCγ at Tyr1217. No activation of BTK was detected 374 
in Xid mice, even after CLP injury and the phosphorylation of cardiac BTK at Tyr223 and the 375 
phosphorylation of PLCγ at Tyr1217 in Xid-CLP mice were similar to that of sham-operated 376 
animals (Figure 5A-B).  377 
 378 
NF-kB activation plays a key role in the pathophysiology of sepsis. When compared to sham-379 
operated mice, WT-CLP mice exhibit a significant increase in NF-kB activation as 380 
demonstrated by significant increases in the phosphorylation of IKKα/β at Ser176/180 and the 381 
phosphorylation of IkBα at Ser32/36. When compared to WT-CLP mice, Xid-CLP mice the 382 
phosphorylation of IKKα/β at Ser176/180 and IkBα at Ser32/36 was significantly reduced, indicating 383 
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that the degree of activation of NF-kB caused by sepsis in the heart was significantly lower in 384 
Xid-mice than in WT-mice (Figure 5C-D).  385 
 386 
When compared to sham-operated mice, WT mice subjected to CLP showed an increase in the 387 
activation of the NLRP3 inflammasome, demonstrated by an increase in the expression of the 388 
NLRP3 inflammasome and cleavage of pro-caspase-1 to caspase-1 in the heart (Figure 5E-F) 389 
as well as an increase the production of IL-1b in serum (Figure 2C). In contrast, Xid-CLP mice 390 
showed reduced activation of NLRP3 inflammasome as demonstrated by a decrease in the 391 
expression of the NLRP3 inflammasome, cleavage of pro-caspase-1 to caspase-1 (Figure 5E-392 
F) and IL-1b when compared to WT-CLP mice (Figure 2C). 393 
 394 
Xid mice show lower levels of sepsis-dysregulated metabolites 395 
Using a targeted metabolomic approach, we detected 240 analytes in murine plasma. A two-396 
dimensional principal component analysis (PCA) of all detected analytes (Figure 6), revealed 397 
a clear distinction between the two sham-operated mice groups (WT sham and Xid sham), the 398 
WT-CLP mice group and the three treated and/or Xid CLP-induced mice groups (Xid CLP, 399 
WT CLP + Ibrutinib and Xid CLP + Ibrutinib). The first principal component explained about 400 
36 % of total variation among the six mice groups and separated the sham-operated mice from 401 
the CLP-induced mice groups. The second principal component explained about 13 % of total 402 
variation of all metabolites and achieved the same effect as PC2, but further it separated the 403 
CLP-induced WT mice group from the three mice groups Xid CLP, WT CLP + ibrutinib and 404 
Xid CLP + ibrutinib. Significant changes in analytes were identified and analyzed via 405 
hierarchical clustered z score heatmaps and their significant log2 fold changes of selected 406 
group comparisons were shown in log2 fold change heatmaps (Figure S2-S5). The heatmaps 407 
illustrate 55 significant primary metabolites (Figure S2), 138 significant phospholipids and 408 
their derivatives (Figure S3-S4) and 6 significant lipid mediators (Figure S5). 409 
 410 
Figure 7 shows a sorting of 24 analytes that were significantly restored in the three mice groups 411 
Xid-CLP, WT-CLP + ibrutinib and Xid-CLP + ibrutinib to the initial levels of both sham-412 
operated groups compared to the WT-CLP mice group. The ibrutinib treatment or the BTK 413 
inactivation or the combination of both restored 7 significant decreased and 17 significant 414 
increased analytes in CLP-induced WT-mice. The decreased analytes belonged predominantly 415 
to the lipid mediator’s docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lyso-416 
platelet activating factor (lyso-PAF) and oleoylethanolamine (OEA). The bile acid 417 
taurodeoxycholic acid (TDCA), the phosphatidylinositol (PI) (34:2) and the primary metabolite 418 
niacinamide were also reduced. The increased analytes included 5 primary metabolites 419 
(dihydroxyphenylalanine (DOPA), creatine, carnosine, nicotinic acid, cytosine), 4 420 
lysophosphatidylserines, 5 phosphatidylserines, 1 lysophosphatidylethanolamine, 1 421 
lysophaphatidylglycerol and 1 phosphytidylethanolamine.  422 
 423 
Sorting by analytes that were only significantly restored in Xid-CLP (Figure S6) showed 5 424 
analytes. One analyte was increased, the primary metabolite kynurenine, and 4 analytes were 425 
decreased in the WT-CLP group and this included the primary metabolite uridine and one the 426 
phospholipids phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol. 427 
Twenty-three analytes showed the sorting by significantly restored analytes in the mice groups 428 
Xid CLP and Xid CLP + Ibrutinib (Figure S7). The levels of 10 analytes (cGMP, creatinine, 429 
ursodeoxycholic acid (UDCA), deoxycholic acid (DCA), adenine, 1 lysophosphatidylserine, 430 
1 lysophosphatidylglycerol, 3 lysophosphatidylethanolamines) were upregulated and 13 431 
analytes (1 sphingomyelin, 6 phosphatidylcholines, 3 phosphatidylethanolamines, 432 
 10 
2 phosphatidylserines, 1 phosphatidylinositol) were downregulated in CLP-induced wildtype 433 
mice. Analytes that were only restored in the mice group WT-CLP + ibrutinib could not be 434 
determined. The heatmap with analytes that were significantly restored in the mice groups WT-435 
CLP + ibrutinib and Xid-CLP + ibrutinib (Figure S8) showed 1 increased primary metabolite 436 
(cholesterol) and 3 decreased phospholipids (2 phosphatidylserines and 437 
1 lysophosphatidylserine). Detailed statistical information of the detectable analytes is shown 438 
in the Supplementary Data section. 439 
Expression of BTK is increased in whole human blood of septic non-survivors  440 
Parnell et al. collected whole blood of patients confirmed with sepsis (and healthy participants) 441 
over a 5-day time course with the first day of collection being within the initial 24 h of 442 
admission to the ICU (26). RNA was extracted from whole blood and gene expression was 443 
analysed by microarray. Three groups were collected, healthy participants, septic survivors and 444 
septic non-survivors. Dataset is available on the gene expression omnibus under GDS4791. We 445 
reanalysed this dataset for BTK expression in these three groups and found that at day 1 there 446 
is no significant differences in gene expression between healthy, septic survivors and septic 447 
non-survivors (Figure 8A&B). However, over the course of 5 days BTK expression increases 448 
in septic non-survivors and a significant difference between non-survivors and healthy 449 
participants as well as a significant difference between non-survivors and survivors is observed 450 
at day 5 (Figure 8C). There was no significant difference in BTK expression between septic 451 
survivors and healthy volunteers (Figure 8A-C).  452 
 453 
Discussion  454 
Sepsis is the overwhelming host response to infection (bacterial, fungal or viral) leading to 455 
shock and multiple organ dysfunction. We have previously reported that BTK inhibitors 456 
(ibrutinib, acalabrutinib) significantly attenuate sepsis-induced cardiac dysfunction and 457 
reduced inflammatory cytokine production, but BTK inhibitors have many off target effects 458 
(14). In the present study we investigated whether the beneficial effects are exclusively due to 459 
inhibition of BTK and how a reduction in systemic inflammation due to BTK loss of function 460 
mutation affects bacterial clearance in vivo. We addressed these questions by conducting a 461 
model of polymicrobial sepsis in Xid mice (which have a missense mutation in the BTK gene, 462 
resulting in BTK to be functionally impaired). We report here for the first time that Xid mice 463 
are protected from sepsis-induced multiple organ dysfunction (cardiac, renal and 464 
hepatocellular) due to increased bacterial clearance and suppression of systemic inflammation 465 
(cytokine storm) (please see Figure 9 for schematic diagram of the role of BTK in the 466 
pathophysiology of sepsis). 467 
 468 
BTK inactivation prevents sepsis-induced multiple organ dysfunction  469 
Sepsis results in multiple organ failure including cardiac dysfunction, renal dysfunction and 470 
hepatocellular injury. We report here for the first time that Xid mice subjected to sepsis are 471 
protected from developing cardiac dysfunction, hepatocellular injury and renal dysfunction. 472 
Most notably, ibrutinib significantly reduced sepsis-induced multiple organ failure in WT-mice 473 
but had no further beneficial effect in Xid-mice subjected to CLP-indicating that the observed 474 
beneficial effect of ibrutinib in WT-mice can solely be explained by inhibition of BTK-activity. 475 
We have previously reported that inhibition of BTK by ibrutinib or acalabrutinib attenuate 476 
sepsis-induced cardiac and renal dysfunction in C57Bl/6 mice (14) and additionally we have 477 
now shown that delayed administration of ibrutinib in WT-CLP (CBA background) also 478 
attenuates sepsis-induced cardiac dysfunction, renal dysfunction and hepatocellular injury, 479 
confirming that BTK inhibitors work in two different genetic backgrounds of mice. 480 
Furthermore, in this study we find that administration of ibrutinib (which inhibits a significant 481 
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number of kinases in addition to BTK, more than acalabrutinib) in Xid-CLP mice neither results 482 
in further beneficial effects nor any adverse effects on cardiac, renal or liver (dys)function. 483 
Inhibition of BTK reduces disease severity in animal models of sepsis-induced lung injury 484 
(29,30), warm liver ischemia and reperfusion (31) and spontaneous lupus nephritis (32). Thus, 485 
we here provide evidence that inhibition of BTK alone is sufficient to prevent sepsis-induced 486 
multiple organ injury. 487 
 488 
BTK inactivation results in enhanced bacterial phagocytosis 489 
We then investigated the mechanism(s) by which inactivation of BTK protects mice against 490 
sepsis-induced multiple organ failure. In septic patients, an essential treatment is early source 491 
control (removal of infection), which is associated with improved outcomes (33). We found 492 
that CLP in Xid mice results in a reduction of the number of bacteria in both peritoneum and 493 
blood (at 24 h after onset of CLP) when compared to WT-CLP mice. This may well be due to 494 
an increase in bacterial phagocytosis in Xid mice. Macrophages obtained from Xid-mice do not 495 
show defects in in phagocytosis (34,35) and we found that the percentage of phagocytosing 496 
cells are similar in both WT and Xid mice. We discovered, however, that macrophages obtained 497 
from Xid-mice with sepsis had taken up a significantly larger number of bacteria. This was also 498 
true for neutrophils from Xid-mice. We believe that the increase in phagocytosis by 499 
macrophages and neutrophils from Xid-mice in vivo could explain the observed increase in 500 
clearance of bacteria in peritoneum and blood. Beguem et al. found that monocytes from 501 
healthy volunteers stimulated with LPS and treated with evobrutinib resulted in an increased 502 
rate of phagocytosis in vitro due to a switch of macrophages from the pro-inflammatory M1 to 503 
the pro-resolving M2 phenotype and this was associated with reduced secretion of TNF-a (36). 504 
In addition, Xid mice infected with F. tularensis showed enhanced bacterial clearance from the 505 
lung and spleen, which correlated with a significant improvement of survival when compared 506 
to wild-type controls (37).  507 
This raises the question of the underlying mechanisms that enables or drives increased 508 
phagocytosis in Xid-mice? Neither inhibition of BTK activity with ibrutinib nor inactivation of 509 
BTK in Xid mice affects monocyte FcgR-mediated phagocytosis, but it does supress FcgR-510 
mediated cytokine production. The decrease of calcium flux due to BTK inhibition also does 511 
not affect phagocytosis, but does decrease cytokine production (34). BTK inhibition results in 512 
the polarisation to M2 macrophages (which have greater phagocytic ability (38)), demonstrated 513 
by increased expression of CD206. CD206 is involved in phagocytosis of a number of bacterial 514 
strains. For example, monocyte-derived macrophages that express high levels of CD206 515 
phagocytosed 78% of E.coli, while monocyte-derived macrophages that express low levels of 516 
CD206 only phagocytosed 30% of E.coli (39). Excessive activation of neutrophils is known to 517 
decrease survival and enhance susceptibility to subsequent bacterial infections (40). One 518 
mechanism that may contribute to the pathology of sepsis is the release of neutrophil 519 
extracellular traps as they contain the beneficial antimicrobial nuclear proteins but also 520 
damaging citrullinated histones, elastase, myeloperoxidase and MMP-3 (41,42). The release of 521 
neutrophil extracellular traps results in ineffective phagocytosis (43). Florence et al. showed 522 
that BTK was increased in the lung neutrophils and inhibiting BTK protected mice against 523 
lethal influenza by reducing the release of neutrophil extracellular traps. The decrease of 524 
neutrophil extracellular traps was also observed in human peripheral blood neutrophils 525 
incubated with influenza and BTK inhibitor (30). However, the exact molecular mechanisms 526 
underlying this phenomenon are yet to be elucidated. Future studies are required to increase 527 
our understanding as to how Xid macrophages and neutrophils phagocytose more bacteria per 528 
immune cell. 529 
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BTK inactivation results in reduced infiltration of the peritoneum with innate immune 530 
cells 531 
BTK plays a fundamental role in signalling and function of B cells, but BTK is also highly 532 
expressed in myeloid cells such as macrophages and neutrophils (9) and inactivation of BTK 533 
results in reduced cell-mediated inflammatory responses  (44,45). We report here that Xid-CLP 534 
mice have reduced infiltrating innate immune cells (macrophages and neutrophils) in the 535 
peritoneum (site of infection). We propose that this may lead to a reduction of the formation 536 
of cytokines/chemokines in the serum and, hence, will prevent the cytokines storm.   537 
 538 
BTK inactivation results in M2 polarisation 539 
Macrophages play an important role in the two phases of sepsis (early pro-inflammatory phase 540 
and the later anti-inflammatory phase), as they can have either pro-inflammatory or anti-541 
inflammatory properties. Initially, M1 macrophages (pro-inflammatory) activate inflammation 542 
by secreting TNF-α, IL-1β, IL-6 and IL-12 to promote the removal of the pathogen, then M2 543 
macrophages repair tissue and resolve inflammation by secreting cytokines including IL-10 544 
(46,47). If the M1 macrophage-driven pro-inflammatory response cannot be controlled, the 545 
resultant cytokine storm can be a key driver of the severity of sepsis leading to organ failure 546 
and death (48). From our experiments we conclude that a loss of function or inhibition of BTK 547 
drives the switch from the pro-inflammatory M1 phenotype to pro-resolving M2 phenotype in 548 
response to LPS (49). Here we report that macrophages obtained from septic Xid-mice have a 549 
pro-resolving M2 phenotype, whereas macrophages obtained from septic WT-mice have the 550 
M1 phenotype. Most notably, macrophages of the M2 phenotype have a greater phagocytotic 551 
function resulting in increased clearance of apoptotic cells and an acceleration of resolution 552 
(38). Indeed, M2 macrophages protect against sepsis-induced lung injury (50) and sepsis-553 
induced acute kidney injury (51). Transplantation of M2 macrophages has been suggested as a 554 
potential therapeutic approach for sepsis-induced lung injury (50). 555 
 556 
BTK inactivation reduces the activation of NF-kB 557 
BTK plays a pivotal role in the activation of TLRs and, hence, the signalling steps leading to 558 
the activation of NF-kB (7), which plays a key role in the pathophysiology of septic 559 
cardiomyopathy (52). Here we report that Xid mice subjected to polymicrobial sepsis have a 560 
reduced activation of BTK and NF-kB (measured as phosphorylation of IKKa/b and IkBa) in 561 
the heart. We have previously reported that BTK inhibitors ibrutinib or acalabrutinib reduce 562 
the activation of cardiac BTK and NF-kB in mice subjected to sepsis (14). Furthermore, we 563 
have shown that inhibition of NF-kB activation with an inhibitor of IKK also attenuates the 564 
cardiac dysfunction associated with polymicrobial sepsis (52). Purvis et al. showed that 565 
ibrutinib treatment attenuated the activation of NF-kB and gene expression of cytokines in the 566 
diabetic kidney and liver (45). Thus, we propose that an impairment in the activation of BTK 567 
in Xid mice leads to reduced activation of NF-kB in the heart, which contributes to or accounts 568 
for the observed reduction in organ injury and dysfunction observed in Xid-mice with sepsis.  569 
 570 
BTK inactivation prevents the cytokine storm 571 
Activation of NF-kB leads to an increase in the production of cytokines and chemokines such 572 
as the pro-inflammatory cytokines TNF-a, IL-6, IL-1b and the anti-inflammatory cytokine IL-573 
10, neutrophils chemoattractant chemokines (KC & ENA-78), monocyte chemoattractant 574 
chemokines (MCP-1, MIP-1a and MIP-1b) and G-CSF, all of which contribute to the systemic 575 
inflammation and organ dysfunction associated with sepsis (53). Out of all these cytokines, the 576 
ones increased most in our model of murine sepsis were IL-6, KC and MCP-1. The levels of 577 
IL-8 and monocyte chemoattractant protein-1 (MCP-1) are associated with early 48-hr and 28-578 
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day mortality in sepsis patients (54). Most notably, we report that in Xid-mice subjected to 579 
CLP-sepsis, all of these cytokines and chemokines are markedly reduced. WT-CLP mice 580 
treated with ibrutinib also show reduced production of sepsis-associated cytokines and 581 
chemokines and no difference is observed with the addition of ibrutinib to Xid-CLP mice. Thus, 582 
an impairment of BTK activation in Xid-mice prevents NF-kB and NLRP3-dependent, 583 
systemic inflammation (cytokine storm) resulting in a reduction in organ injury/dysfunction.  584 
 585 
BTK inactivation reduces the activation of the NLRP3 inflammasome 586 
BTK is also involved in the assembly/activation of the NLRP3 inflammasome in both mice 587 
and humans (8,55). The activation of the NLRP3 inflammasome also plays a role in the 588 
pathophysiology of sepsis and septic cardiomyopathy (56). Pharmacological inhibition of 589 
NLRP3 activation with MCC950 (NLRP3 inflammasome inhibitor) reduced the neurological 590 
and cognitive impairment in septic animals (57). It has also been reported that genetic 591 
deficiency of NLRP3 promotes resolution of inflammation in polymicrobial sepsis (58). We 592 
report here that the activation of the NLRP3 inflammasome (measured as NLRP3 activation, 593 
caspase-1 activation and IL-1b release) was largely reduced in Xid-mice subjected to CLP 594 
when compared to WT-mice with sepsis. We previously reported that BTK inhibitors (ibrutinib 595 
or acalabrutinib) inhibit the activation of the NLRP3 inflammasome and production of IL-1b 596 
in septic animals (14). Purvis et al. showed that ibrutinib treatment also attenuated the 597 
activation NLRP3 inflammasome in the diabetic kidney and liver (45). Thus, we propose that 598 
prevention of the activation of the NLRP3 inflammasome secondary to reduced activation of 599 
BTK importantly contributes to the reduction in inflammation and organ dysfunction observed 600 
in septic Xid-mice.  601 
BTK inactivation restores dysregulated metabolites 602 
PCA showed that 49% of the total variance of all metabolites formed three well separable 603 
clusters. The metabolomic profiles of CLP-induced WT mice formed one cluster and was 604 
clearly distinguishable from a second cluster (WT sham-operated and Xid sham-operated) and 605 
a third cluster consisting of the three groups Xid-CLP, WT-CLP + ibrutinib and Xid-606 
CLP + ibrutinib. The common clustering of the latter three groups supports the assumption that 607 
the inhibition of BTK alone is responsible for the partial restoration of dysregulated metabolites 608 
in sepsis. 609 
 610 
Host defense toward bacterial infection is a complex interplay of several mechanisms including 611 
inflammation, coagulation, immune activation, hypoxia and metabolic reprogramming. 612 
Specifically, the regulation and impact of the metabolic changes is known to play an important 613 
role in the pathophysiology of sepsis (59). We demonstrated in this study that deregulated 614 
members of lipid mediators, phospholipids, primary metabolites and bile acids in CLP-induced 615 
WT-mice were restored by ibrutinib (in WT-mice) and/or by inactivation of the BTK gene 616 
(Xid-mice). The elevated and reduced plasma levels of some restored metabolites in the WT 617 
CLP group were already shown. For example, an increased metabolism of the lipid mediators 618 
AA and EPA could be found in plasma of sepsis patients (60). In addition, two other lipid 619 
mediators, OEA and lyso-PAF, were decreased in CLP-induced WT mice. Platelet-activating 620 
factor (PAF) is a proinflammatory mediator in systemic inflammation and its known to be 621 
upregulated in sepsis (61). Degradation of the immediate precursor lyso-PAF is probably a 622 
result of its increased transformation to PAF (62). The decreased levels of the lipid-amide OEA 623 
are probably a compensatory mechanism in sepsis-related weight loss and disturbed energy 624 
balance, because OEA is a modulator in food consumption and weight management and 625 
actually leads to satiation or meal termination (63). Even the restoration of the reduced bile 626 
acid TDCA and the elevated amino acid DOPA seems to be a positive regulatory mechanism. 627 
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TDCA ameliorates systemic inflammation, normalizes blood pressure, prevents kidney injury 628 
and prolongs survival in a mouse sepsis model (64). DOPA has anti-neuro inflammation effects 629 
and improved neuroplasticity in septic mice (65). The plasma of the WT-CLP group showed 630 
also increased levels of isoforms of the phospholipids species lysophaphatidylserine and PS, 631 
probably due to their procoagulant activity in sepsis (66,67). Some primary metabolites were 632 
also enhanced in septic mice and restored by ibrutinib administration and BTK inactivation 633 
such as the dysregulated precursors (cytosine, niacinamide, nicotinic acid) of nucleotide or 634 
nicotinate and nicotinamide metabolism (68,69). The restoration also included the loss of 635 
carnosine to plasma due to skeletal muscle wasting in sepsis (70) and the elevated levels of 636 
creatine presumably because of the known higher activity of creatine kinase to catalyze the 637 
urgently required ATP in developing sepsis (71). This data of restored metabolites 638 
demonstrates that Xid mice with a deficiency in BTK have a similar metabolomic profile in 639 
sepsis than WT-CLP-mice treated with ibrutinib. 640 
 641 
In addition, the data in figures S5 and S6 reveal that Xid mice restored metabolites 7 times 642 
more than ibrutinib-treated mice (Fig. S7). Many of the additionally restored metabolites in 643 
Xid mice are known to be deregulated in sepsis such as adenine (72) creatinine (73) and 644 
kynurenine (74). An explanation for the different magnitude of restored metabolites in 645 
Xid mice in comparison with ibrutinib-treated mice could be the different number of inhibited 646 
kinases. Thus, the Xid mice seem to benefit from the inhibition of only one kinase, namely 647 
BTK, which in addition to reducing cytokine storm restores the sepsis-related dysregulation of 648 
specific metabolites. 649 
 650 
BTK expression is increased in whole human blood of septic non-survivors 651 
Currently the expression and/or activation of BTK in septic patients has not been reported. 652 
There are datasets available on the GEO and we reanalysed microarray data (GDS4971) of the 653 
time course of gene expression in healthy, septic survivors and septic non-survivors published 654 
by Parnell et al. (26). Interestingly, our analysis revealed an increase in expression of BTK in 655 
septic non-survivors, whereas BTK expression in septic survivors does not increase and is not 656 
different from healthy volunteers. Thus, increases in BTK expression in septic patients 657 
correlate with mortality, while lower levels of BTK expression are associated with survival 658 
from sepsis. There were no clear differences between cytokine expression of TNF-a, IL-6, 659 
MCP-1, CXCL1 in the three groups, expression of BTK was a better predictor of mortality 660 
rather than with the expression of any one cytokine.  We have previously shown in septic mouse 661 
hearts that activation of BTK correlates with cardiac dysfunction (14). BTK activation also 662 
increases in whole blood of COVID-19 patients which, like septic patients, also present with 663 
excessive systemic inflammation (cytokine storm) (17).  664 
 665 
Limitations of the Study 666 
We have shown that Xid-mice subjected to CLP have increased bacterial clearance and reduced 667 
systemic inflammation (secondary to reduced activation of the NLRP3 inflammasome and NF-668 
kB) and cardiac (organ) dysfunction. There is good evidence that mortality of patients with 669 
sepsis increases with an increase in the number of organs failing (SOFA scores). In the UK 670 
survival studies in septic models are not routinely conducted due to ethical reasons. Thus, we 671 
were unable to investigate the survival of Xid mice undergoing sepsis. It has been reported that 672 
a reduction in temperature <30oC or a change of temperature of 5oC over time predicts mortality 673 
in animals with sepsis (28). Using this more humane surrogate marker, we found that Xid mice 674 
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with sepsis have a predicted mortality of 0% (100% survival), while WT-mice with sepsis 675 
would have a predicted mortality of 90% (10% survival). We found that ibrutinib does not 676 
affect predicted mortality in Xid-CLP resulting in a predicted mortality of 0% (100% survival) 677 
and that delayed administration of ibrutinib in WT-CLP mice led to a predicated mortality of 678 
15% (85% survival). It would be useful to confirm the impact of an impairment in BTK 679 
function in Xid-mice on outcome (mortality) in a more long-term sepsis model.  680 
 681 
Conclusion 682 
We report here for the first time that genetic inactivation of BTK is responsible for conferring 683 
protection against multiple organ failure in a clinically relevant model of sepsis. Most 684 
importantly we have shown that the inactivation of BTK in Xid mice results in an increase of 685 
bacterial phagocytosis in macrophages and neutrophils, thus, increasing bacterial clearance in 686 
both peritoneum and blood. Inactivation of BTK also results in a phenotypic switch of 687 
macrophages from M1 to the M2 phenotype, which aids in the resolution of sepsis. The 688 
suppression of the immune system by inactivated BTK leads to reduced activation of NF-κB 689 
and the NLRP3 inflammasome, therefore, preventing the induction of the cytokine storm. 690 
Metabolomic analysis revealed a dysregulation of metabolites in WT septic mice. Most 691 
notably, we found that inactivation of BTK in Xid-mice or administration of ibrutinib in WT 692 
mice is responsible for the (partial) restoration of dysregulated metabolites in sepsis. As the 693 
administration of ibrutinib to Xid-CLP mice did not result in any additional (beneficial) effects 694 
on the alterations in organ dysfunction, cytokine/chemokines formation and changes in 695 
metabolites caused by sepsis, our data strongly suggest that BTK inactivation is responsible 696 
for the observed effects of ibrutinib. Lastly, we have found that BTK expression in humans is 697 
increased in the blood of septic non-survivors, while lower expression is associated with 698 
survival from sepsis. Taken together our work suggests that BTK inhibitors maybe repurposed 699 
for the use in sepsis (or other conditions associated with excessive local or systemic 700 
inflammation including COVID-19) due to their ability to reduce systemic inflammation 701 
(cytokine storm), their ability to enhance the phagocytosis of macrophages and switch 702 
macrophages from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype.   703 
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Figure 1. Xid mice are protected from sepsis-induced multiple organ failure. WT and Xid 989 
mice were randomly selected to undergo sham or CLP surgery, 1 h later ibrutinib (30 mg/kg) 990 
was administered intravenously. At 24 h after CLP, cardiac function was assessed by 991 
echocardiography and parameters of renal and liver function were assessed in serum. (A) 992 
Severity Score 24 h after CLP. (B) Temperature 24 h after CLP (oC). (C) Predicted percentage 993 
of survival (%). (D) Heart rate 24 h after CLP (bmp). (E) Representative m-mode images. (F) 994 
 23 
Ejection Fraction (%). (G) Fractional shortening (%). (H) Fractional area change (%). (I) 995 
Cardiac output (ml/min). (J) Stroke volume (µL). (K) Myocardial performance index (NFT). 996 
(L) Urea (mmol/L). (M) Creatinine (µmol/L). (N) Lactate dehydrogenase (U/L). (O) ATL 997 
(U/L). (P) AST (U/L). The following groups were studied WT sham (n = 5), Xid sham (n = 5), 998 
WT-CLP (n = 10), Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8) and Xid-CLP + ibrutinib (n 999 
= 6). Data are expressed as mean ± SEM and analysed by one-way ANOVA with a Bonferroni 1000 
post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 ****P < 0.0001 versus WT-CLP.  1001 
  1002 
 24 
 1003 
Figure 2. Xid mice do not present with systemic inflammation after polymicrobial sepsis. 1004 
Mice underwent sham or CLP surgery, 24 h later cytokines and chemokines were assessed in 1005 
serum. (A) TNF-a serum concentration (pg/ml). (B) IL-6 serum concentration (pg/ml). (C) IL-1006 
1b serum concentration (pg/ml). (D) IL-10 serum concentration (pg/ml). (E) KC/CXCL1 1007 
serum concentration (pg/ml). (F) ENA-78/CXCL5 serum concentration (pg/ml). (G) GM-CSF 1008 
serum concentration (pg/ml). (H) MCP-1/CCL2 serum concentration (pg/ml). (I) MIP-1009 
1a/CCL3 serum concentration (pg/ml). (J) MIP-1b/CCL4 serum concentration (pg/ml). (K) 1010 
Heat-map of 31 cytokines/chemokines serum concentration (pg/ml). The following groups 1011 
were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10), Xid-CLP (n = 10), WT-1012 
CLP + ibrutinib (n = 8) and Xid-CLP + ibrutinib (n = 6). Data are expressed as mean ± SEM 1013 
and analysed by one-way ANOVA with a Bonferroni post hoc test. *P < 0.05, **P < 0.01, 1014 
***P < 0.001 ****P < 0.0001 versus WT-CLP. 1015 
 25 
 1016 
Figure 3. Xid mice have fewer infiltrating immune cells in the peritoneum and enhanced 1017 
polarisation to M2 macrophages. Mice underwent sham or CLP surgery, 24 h later peritoneal 1018 
lavage fluid was analysed. (A) Scattergrams illustrating macrophage (identified as 1019 
F4/80+Ly6G-) and neutrophils (identified as F4/80-Ly6G+). (B) Peritoneal neutrophil (F4/80-1020 
Ly6G+) cell count per ml. (C) Peritoneal macrophage (F4/80+Ly6G-) cell count per ml. (D) 1021 
Contour plot illustrating percentage of M1 and M2 macrophages in WT and Xid mice, M1 1022 
identified as MHCII+CD206- and M2 identified as MHCII+CD206+. (E) Percentage of M1 and 1023 
M2 macrophages in WT mice and Xid mice (%). The following groups were studied WT sham 1024 
(n = 5), Xid sham (n = 5), WT-CLP (n = 10) and Xid-CLP (n = 10). Data are expressed as mean 1025 
± SEM and analysed by one-way ANOVA with a Bonferroni post hoc test. *P < 0.05, ***P < 1026 
0.001 ****P < 0.0001 versus WT-CLP. 1027 
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 1028 
Figure 4. Xid mice result in enhanced bacterial clearance in peritoneum and blood due to 1029 
increased phagocytosis in sepsis. Mice underwent sham or CLP surgery, 24 h later peritoneal 1030 
lavage fluid and blood were analysed. Macrophages identified as (CD11b+, F4/80+ and Ly6G-1031 
) and neutrophils identified as (CD11b+, F4/80- and Ly6G+) (A) Representative images of 1032 
peritoneal bacteria cell count. (B) Peritoneum bacteria cell count per ml.  (C) Representative 1033 
images of blood bacteria cell count. (D) Blood bacteria cell count per ml. (E) Representative 1034 
images of WT-CLP macrophages phagocytosis on the imagestream. (F) Representative images 1035 
of Xid-CLP macrophages phagocytosis on the imagestream. (G) Percentage of phagocytosing 1036 
macrophages (%). (H) Average number of pHrodo red E.coli BioParticles within macrophages. 1037 
(I) Representative images of WT-CLP neutrophil phagocytosis on the imagestream. (J) 1038 
Representative images of Xid-CLP neutrophil phagocytosis on the imagestream. (K) 1039 
Percentage of phagocytosing neutrophils (%). (L) Average number of pHrodo red E.coli 1040 
BioParticles within neutrophils. The following groups were studied WT sham (n = 5), Xid sham 1041 
(n = 5,) WT-CLP (n = 10) and Xid-CLP (n = 10). Data are expressed as mean ± SEM and 1042 
analysed by one-way ANOVA with a Bonferroni post hoc test. **P < 0.01, ***P < 0.001 1043 
****P < 0.0001 versus WT-CLP. 1044 
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 1045 
Figure 5. BTK, NF-kB and NLRP3 inflammasome are not activated in Xid mice after 1046 
polymicrobial sepsis. Mice underwent sham-operated or CLP surgery and 24 h later signalling 1047 
events in the cardiac tissue were assessed. Densitometric analysis of the bands is expressed as 1048 
relative optical density (O.D.) of (A) phosphorylation of BTK at Tyr223 corrected for the 1049 
corresponding total BTK and normalized using the related sham bands. (B) Phosphorylation of 1050 
PLCg at Tyr1217 corrected for the corresponding total PLCg and normalised using the related 1051 
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sham bands. (C) Phosphorylation of IKKa/b at Ser176/180 corrected for the corresponding total 1052 
IKKa/b and normalised using the sham related bands. (D) Phosphorylation of IkBa at Ser32/36 1053 
corrected for the corresponding total IkBa and normalised using the related sham band. (E) 1054 
NLRP3 activation, corrected against tubulin and normalized using the sham related bands. (F) 1055 
Pro-caspase-1 against activated caspase-1 and normalized using the sham related bands. The 1056 
following groups were studied WT sham (n = 4), Xid sham (n = 4), WT-CLP (n = 4) and Xid-1057 
CLP (n = 4). Data are expressed as mean ± SEM and analysed by one-way ANOVA with a 1058 
Bonferroni post hoc test. ***P < 0.001 ****P < 0.0001 versus WT-CLP. 1059 
 1060 
Figure 6. Principal component analysis (PCA). Principal component analysis (PCA) of the 1061 
normalised and scaled metabolome data. Plot shows first two principal components (PC), 1062 
which account for almost half of the total variance in the data set. Variance between replicates 1063 
is far less than between different experimental conditions. Contrasts between main 1064 
experimental conditions are visible in the shown PCs. Each dot represents a sample and each 1065 
colour represents a mice group. 1066 
 29 
 1067 
Figure 7. Heatmap of significant restored metabolites in the groups XID CLP, 1068 
WT CLP + Ibrutinib and XID CLP + Ibrutinib. (A) Hierarchical clustered z score 1069 
heatmaps showed significantly changed analytes and (B) log2 fold change heatmaps showed 1070 
their significant log2 fold changes for selected groupwise comparisons. The heatmap shows 1071 
analytes which, compared to the WT CLP group (n = 10), restored in all three groups (Xid-1072 
CLP (n = 10), WT-CLP + ibrutinib (n = 8) and Xid-CLP + ibrutinib (n = 6)) to the level of the 1073 
two sham groups (WT Sham (n = 5), Xid Sham (n = 5)). Each column in a z score heatmap 1074 
represented the mean value of all animals in a group, each column in a log2 fold change 1075 
heatmap represented a groupwise comparison and each row defined an analyte. Analytes were 1076 
hierarchically clustered using Ward's minimum variance method (75) and an euclidian distance 1077 
between log2 fold changes. Dendrograms provide information about distances between 1078 
clusters. AA: arachidonic acid, AEA: arachidonoylethanolamide, DHA: docosahexaenoic acid, 1079 
DOPA: dihydroxyphenylalanine, EPA: eicosapentaenoic acid, LPE: 1080 
lysophosphatidylethanolamine, LPG: lysophosphatidylglycerol, LPS: lysophosphatidylserine, 1081 
lyso-PAF: lyso-platelet activating factor, OEA: oleoylethanolamine, PE: 1082 
phosphatidylethanolamine, PI: phosphatidylinositol, PS: phosphatidylserine, TDCA: 1083 
taurodeoxycholic acid. 1084 
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 1085 
Figure 8. Expression of BTK is increased in whole human blood of septic non-survivor’s 1086 
Original data was obtained from the gene expression omnibus under dataset number GDS4971 1087 
which was published by Parnell GP et al. Whole blood of patients confirmed with sepsis (and 1088 
healthy participants) over a 5-day time course. RNA was extracted from whole blood and 1089 
analysed for gene expression via microarray Illumina GenomeStudio V2010.3. Three groups 1090 
were collected, healthy participants, septic survivors and septic non-survivors. (A) Time course 1091 
of BTK expression. (B) Day 1 BTK expression. (C) Day 5 BTK expression. Data was 1092 
reanalysed looking for expression of BTK gene in their dataset and generated the figure using 1093 
the software R, gene expression was quantile normalization and log transformation of the data 1094 
was applied. Significance was determined by one-way ANOVA followed by Bonferroni post 1095 
hoc test and a value of *P < 0.05 and ***P < 0.001 were considered significant. Data are 1096 
expressed as mean ± SEM. Day 1 healthy (n = 18), septic survivors (n = 26), septic non-1097 
survivors (n = 9). Day 2 septic survivors (n = 24), septic non-survivors (n = 7). Day 3 septic 1098 
survivors (n = 22), septic non-survivors (n = 7). Day 4 septic survivors (n = 13), septic non-1099 




Figure 9. Schematic diagram representing the role of Bruton’s tyrosine kinase (BTK) in 1103 
the pathophysiology of sepsis. LPS is released from Gram-negative bacteria which activate 1104 
the TLR4 signalling pathway and the release of PepG from Gram-positive bacteria activate the 1105 
TLR2 signalling pathway. BTK is involved in the activation of TLR4 and TLR2 by binding to 1106 
MyD88 and TRIF thus activating their representative signalling cascades. The activation of the 1107 
MyD88 signalling pathway, leads to the activation of NF-kB and the production of pro-1108 
inflammatory cytokines. Additionally, BTK activates the NLRP3 inflammasome by binding to 1109 
the ASC component of the inflammasome. Once active the NLRP3 inflammasome cleaves pro-1110 
IL-1b to active IL-1b. The production of chemokines from NF-kB activation results in the 1111 
recruitment of neutrophils and macrophages. Excessive inflammation from the cytokine storm 1112 
and innate immune cells results in multiple organ failure/injury. The use of BTK inhibitors 1113 
such as ibrutinib or acalabrutinib supress sepsis-induced inflammation and thus multiple-organ 1114 
failure/injury. 1115 

















Figure S2. Heatmaps of primary metabolites. Hierarchical clustered z score heatmaps showed
significantly changed primary metabolites (A) and log2 fold change heatmaps showed their significant
log2 fold changes for selected groupwise comparisons (B). Each column in a z score heatmap represented
an animal and each column in a log2 fold change heatmap represented a groupwise comparison and each
row defined an analyte. Primary metabolites were divided in five groups: amino acids, nucleosides and
nucleotides, organic acids, bile acids and others. Analytes were hierarchically clustered using Ward's
minimum variance method and an euclidian distance between log2 fold changes. Dendrograms provide
information about distances between clusters. cAMP: cyclic adenosine monophosphate, DOPA:
dihydroxyphenylalanine, TDCA: taurodeoxycholic acid, UDCA: ursodeoxycholic acid, DCA:














Figure S3. Heatmaps of phospholipids I. (A) Hierarchical clustered z score heatmaps showed significantly
changed primary metabolites. (B) log2 fold change heatmaps showed their significant log2 fold changes for
selected groupwise comparisons Each column in a z score heatmap represented an animal and each column in a
log2 fold change heatmap represented a groupwise comparison and each row defined an analyte. Phospholipids
were divided in LPC and PC, LPS and PS and LPG. Analytes were hierarchically clustered using Ward's
minimum variance method and an euclidian distance between log2 fold changes. Dendrograms provide
information about distances between clusters. LPC: lysophosphatidylcholine, PC: phosphatidylcholine, LPS:














Figure S4. Heatmaps of phospholipids II. (A) Hierarchical clustered z score heatmaps showed significantly changed phospholipids.
(B) log2 fold change heatmaps showed their significant log2 fold changes for selected groupwise comparisons Each column in a z
score heatmap represented an animal and each column in a log2 fold change heatmap represented a groupwise comparison and each
row defined an analyte. Phospholipids were divided in LPE and PE, LPI and PI and sphingolipid metabolism. Analytes were
hierarchically clustered using Ward's minimum variance method and an euclidian distance between log2 fold changes. Dendrograms
provide information about distances between clusters. LPE: lysophosphatidylethanolamine, PE: phosphatidylethanolamine, LPI:
lysophosphatidylinositol, PI: phosphatidylinositol, SM: sphingomyelins.
Figure S5. Heatmap of lipid mediators. (A) Hierarchical clustered z score heatmaps showed significantly
changed lipid mediators. (B) log2 fold change heatmaps showed their significant log2 fold changes for
selected groupwise comparisons. Each column in a z score heatmap represented an animal and each column
in a log2 fold change heatmap represented a groupwise comparison and each row defined an analyte.
Analytes were hierarchically clustered using Ward's minimum variance method and an euclidian distance
between log2 fold changes. Dendrograms provide information about distances between clusters. AEA:
arachidonoylethanolamide, AA: arachidonic acid, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid,














Figure S6. Heatmap of significant restored metabolites in the group Xid-CLP. (A) Hierarchical clustered
z score heatmaps showed significantly changed metabolites. (B) log2 fold change heatmaps showed their
significant log2 fold changes for selected groupwise comparisons. The heatmap shows metabolites which,
compared to the WT-CLP group (n = 10), restored in the group Xid-CLP (n = 10), but not in the groups WT-
CLP + Ibrutinib (n = 8) and Xid-CLP + Ibrutinib (n = 6) to the level of the two sham groups (WT Sham
(n = 5), Xid Sham (n = 5)). Each column in a z score heatmap represented the mean value of all animals in a
group, each column in a log2 fold change heatmap represented a groupwise comparison and each row defined
an analyte. Analytes were hierarchically clustered using Ward's minimum variance method and an euclidian
distance between log2 fold changes. Dendrograms provide information about distances between clusters. PC:
phosphatidylcholine PE: phosphatidylethanolamine, PI: phosphatidylinositol.
Figure S7. Heatmap of significant restored metabolites in two mice groups: Xid-CLP and Xid -
CLP + Ibrutinib. (A) Hierarchical clustered z score heatmaps showed significantly changed metabolites. (B)
log2 fold change heatmaps showed their significant log2 fold changes for selected groupwise comparisons The
heatmap shows metabolites which, compared to the WT-CLP group (n = 10), restored in the groups Xid-CLP
(n = 10) and Xid CLP + Ibrutinib (n = 6), but not in the WT-CLP + Ibrutinib (n = 8) and) to the level of the two
sham groups (WT Sham (n = 5), Xid Sham (n = 5)). Each column in a z score heatmap represented the mean
value of all animals in a group, each column in a log2 fold change heatmap represented a groupwise comparison
and each row defined an analyte. Analytes were hierarchically clustered using Ward's minimum variance
method and an euclidian distance between log2 fold changes. Dendrograms provide information about distances
between clusters. cGMP: cyclic guanine monophosphate, DCA: deoxycholic acid, LPE:
lysophosphatidylethanolamine, LPG: lysophosphatidylglycerol, LPS: lysophosphatidylserine, PC:
phosphatidylcholine, PE: phosphatidylethanolamine, PI: phosphatidylinositol, PS: phosphatidylserine, SM:




























Figure S8. Heatmap of significant restored metabolites in two mice groups: WT CLP + Ibrutinib and
Xid CLP + Ibrutinib. (A) Hierarchical clustered z score heatmaps showed significantly changed metabolites. (B)
log2 fold change heatmaps showed their significant log2 fold changes for selected groupwise comparisons. The
heatmap shows metabolites which, compared to the WT-CLP group (n = 10), restored in the groups WT-
CLP + Ibrutinib (n = 8) and Xid-CLP + Ibrutinib (n = 6), but not in the Xid-CLP (n = 10) to the level of the two
sham groups (WT Sham (n = 5), Xid Sham (n = 5)). Each column in a z score heatmap represented the mean value
of all animals in a group, each column in a log2 fold change heatmap represented a groupwise comparison and
each row defined an analyte. Analytes were hierarchically clustered using Ward's minimum variance method and
an euclidian distance between log2 fold changes. Dendrograms provide information about distances between
clusters. LPS: lysophosphatidylserine, PS: phosphatidylserine.
Supplementary tables 
Table S1. UHPLC program. Solvent A consisted of 0.1% formic acid in water, solvent B 
consisted of 0.1% formic acid in acetonitrile, solvent C consisted of methanol and solvent D 


















B and C 
curve* 
primary metabolites 
0.01 0.25 100     
2.00 0.25 100     
5.00 0.25 75     
11.00 0.25 65     
15.00 0.25 5     
20.00 0.25 5     
20.01 0.25 100     
25.00 stop      
lipid mediators 
0 0.2 90 10    
10.0 0.2 75 25    
20.0 0.2 65 35    
40.0 0.2 25 75    
40.2 0.2 5 95    
50.0 0.2 5 90    
50.2 0.2 90 10    
59.0 Stop      
phospholipids 
0.0 0.15 80 10  10  
2.0 0.15 80 10  10  
4.0 0.15 60 20  20 -3 
50.0 0.15 7.6 46.2  46.2  
52.0 0.15 0 50  50  
70.0 0.15 0 50  50  
70.2 0.15 80 10  10  
80.0 stop      
sphingosine-1-phosphate and sphingosine 
0 0.4 90  10   
0.01 0.4 0  100   
3.00 0.4 0  100   
5.00 0.8 0  100   
7.00 0.8 0  100   
7.01 0.8 90  10   
7.80 0.8 90  10   
8.30 0.3 90  10   
9.50 0.3 90  10   
9.51 Stop      
*sets the gradient curve of the solvent (-10 to 10) 
 
  
Table S2. Mass spectrometer (LCMS 8050) settings. 
source conditions parameters 
nebulizing gas flow rate 3.0 L/min 
heating gas flow rate 10.0 L/min 
drying gas flow rate 10.0 L/min 
collision-induced dissociation gas pressure 230 kPa 
interface temperature 300 °C 
desolvation line temperature 250 °C 
block heater temperature 400 °C 
ionization mode electrospray ionisation (ESI) 
 
  
Table S3: Mass transitions for identified significantly changed primary metabolites. The 
target ion shows the multiple reaction monitoring (MRM) transitions, the ionization polarity 
(IP) shows the ionization mode of the electrospray ionization (ESI) source and the internal 
standard (IS) column assigns the number of the internal standard to the compounds with which 
they were evaluated. The internal standard is marked in bold letters. Injection volume of 10 µl 
sample. 
no. compound target ion IP IS 
1 4-hydroxyproline 132.10>86.05 + 1 
2 adenine 136.00>119.05 + 1 
3 adenosine monophosphate 348.00>136.05 + 1 
4 adenylsuccinic acid 464.10>252.10 + 1 
5 alanine 89.90>89,90 + 1 
6 arginine 175.10>70.10 + 1 
7 argininosuccinic acid 291.00>70.10 + 1 
8 asparagine 133.10>87.15 + 1 
9 bilirubin 583.30>285.25 - 1 
10 carnitine 162.10>103.05 + 1 
11 carnosine 227.10>110.05 + 1 
12 choline† 104.10>60.05 + 1 
13 cholesterol 369.40>161.30 + 1 
14 citrulline 176.10>70.05 + 1 
15 creatine 132.10>44.05 + 1 
16 creatinine 114.10>44.05 + 1 
17 cystathionine 223.00>88.05 + 1 
18 cystine 241.00>151.95 + 1 
19 cytidine 244.10>112.05 + 1 
20 cytidine 3',5'-cyclic monophosphate (cAMP) 306.00>112.10 + 1 
21 cytidine monophosphate 324.00>112.05 + 1 
22 cytosine 112.00>95.10 + 1 
23 dihydroxyphenylalanine (DOPA) 198.10>152.10 + 1 
24 dimethylarginine (symmetric/asymmetric) 203.10>70.15 + 1 
25 dimethylglycine 104.10>58.05 + 1 
26 flavin adenine dinucleotide 786.15>136.10 + 1 
27 flavin mononucleotide 455.00>97.00 - 1 
28 glutamic acid 147.90>84.10 + 1 
29 glutamine 147.10>84.15 + 1 
30 glutathione 308.00>179.10 + 1 
31 guanosine 3',5'-cyclic monophosphate (cGMP) 346.00>152.05 + 1 
32 guanosine monophosphate 364.00>152.05 + 1 
33 histamine 112.10>95.05 + 1 
34 histidine 155.90>110.10 + 1 
35 isoleucine 132.10>69.15 + 1 
36 kynurenine 209.10>192.05 + 1 
37 leucine 132.10>30.05 + 1 
38 lysine 147.10>84.10 + 1 
39 niacinamide 123.10>80.05 + 1 
40 nicotinic acid 124.05>80.05 + 1 
41 ophthalmic acid 290.10>58.10 + 1 
42 ornithine 133.10>70.10 + 1 
43 phenylalanine 166.10>120.10 + 1 
44 proline 116,10>70,15 + 1 
45 oxidized glutathione 611.10>306.00 - 1 
46 s-adenosylmethionine 399.10>250.05 + 1 
47 serotonin 177.10>160.10 + 1 
48 threonine 120.10>74.15 + 1 
49 thymidine 243.10>127.10 + 1 
50 thymidine monophosphate 322.90>81.10 + 1 
51 tyrosine 182.10>136.10 + 1 
52 uracil 113.00>70.00 + 1 
53 uric acid 167.10>123.95 - 1 
54 uridine 245.00>113.05 + 1 
55 valine 118.10>72.15 + 1 
56 2-morpholinoethanesulfonic acid (IS) 194.00>80.15 - 1 
†illustrated in heatmaps of phospholipids 
  
Table S4: Mass transitions for identified significantly changed phospholipids. The target 
ion shows the multiple reaction monitoring (MRM) transitions, the ionization polarity (IP) 
shows the ionization mode of the ESI source and the internal standard (IS) column assigns the 
number of the internal standard to the lipid species with which they were evaluated. The 
internal standard is marked in bold letters. (LPC: lysophosphatidylcholine, PC: 
phosphatidylcholine, LPE: lysophosphatidylethanolamine, PE: phosphatidylethanolamine, 
LPG: lysophosphatidylglycerol, LPI: lysophosphatidylinositol, PI: phosphatidylinsitol, LPS: 
lysophosphatidylserine, PS: phosphatidylserine, SM: sphingomyelin) 
no. lipid species target ion IP IS 
1 LPC(16:1) 494.3>184.10 + 1 
2 LPC(18:1)* 522.4>184.10 + 1 
3 LPC(18:3) 518.3>184.10 + 1 
4 LPC(20:0) 552.4>184.10 + 1 
5 LPC(20:1) 550.4>184.10 + 1 
6 LPC(20:2) 548.4>184.10 + 1 
7 LPC(20:3) 546.4>184.10 + 1 
8 LPC(20:4)* 544.4>184.10 + 1 
9 LPC(20:5) 542.3>184.10 + 1 
10 LPC(22:0) 580.5>184.10 + 1 
11 LPC(22:1) 578.4>184.10 + 1 
12 LPC(22:6)* 568.4>184.10 + 1 
13 PC(30:0) 706.6>184.10 + 1 
14 PC(30:1)* 704.5>184.10 + 1 
15 PC(30:2)* 702.5>184.10 + 1 
16 PC(32:0)* 734.6>184.10 + 1 
17 PC(32:1)* 732.6>184.10 + 1 
18 PC(32:2) 730.6>184.10 + 1 
19 PC(34:3)* 756.6>184.10 + 1 
20 PC(36:0) 790.7>184.10 + 1 
21 PC(36:1)* 788.6>184.10 + 1 
22 PC(36:3)* 784.6>184.10 + 1 
23 PC(36:5)* 780.6>184.10 + 1 
24 PC(38:1) 816.7>184.10 + 1 
25 PC(38:2)* 814.7>184.10 + 1 
26 PC(38:3)* 812.6>184.10 + 1 
27 PC(38:5)* 808.6>184.10 + 1 
28 PC(38:7)* 804.6>184.10 + 1 
29 PC(38:8) 802.6>184.10 + 1 
30 PC(40:0) 846.7>184.10 + 1 
31 PC(40:1) 844.7>184.10 + 1 
32 PC(40:2) 842.7>184.10 + 1 
33 PC(40:3) 840.7>184.10 + 1 
34 PC(40:4) 838.7>184.10 + 1 
35 PC(40:5)* 836.6>184.10 + 1 
36 PC(40:7)* 832.6>184.10 + 1 
37 PC(40:8) 830.6>184.10 + 1 
38 PC(42:0) 874.8>184.10 + 1 
39 PC(42:1) 872.7>184.10 + 1 
40 PC(42:2) 870.7>184.10 + 1 
41 PC(42:3) 868.7>184.10 + 1 
42 PC(42:4) 866.7>184.10 + 1 
43 PC(42:5) 864.7>184.10 + 1 
44 PC(42:6) 862.7>184.10 + 1 
45 PC(42:7) 860.6>184.10 + 1 
46 PC(42:8) 858.6>184.10 + 1 
47 PC(44:1) 900.8>184.10 + 1 
48 PC(44:6) 890.7>184.10 + 1 
49 PC(44:7) 888.7>184.10 + 1 
50 LPE(14:0) 426.3>285.24 + 1 
51 LPE(14:1) 424.3>283.23 + 1 
52 LPE(16:0) 454.3>313.27 + 1 
53 LPE(16:1) 452.3>311.26 + 1 
54 LPE(18:0) 482.3>341.30 + 1 
55 LPE(18:1) 480.3>339.29 + 1 
56 LPE(18:2) 478.3>337.27 + 1 
57 LPE(18:3) 476.3>335.26 + 1 
58 LPE(20:0) 510.4>369.34 + 1 
59 LPE(20:2) 506.3>365.30 + 1 
60 LPE(20:3) 504.3>363.29 + 1 
61 LPE(20:4) 502.3>361.27 + 1 
62 LPE(20:5) 500.3>359.26 + 1 
63 LPE(22:0) 538.4>397.37 + 1 
64 LPE(22:1) 536.4>395.35 + 1 
65 LPE(22:6) 526.3>385.27 + 1 
66 PE(32:0) 692.5>551.50 + 1 
67 PE(32:1) 690.5>549.49 + 1 
68 PE(32:2) 688.5>547.47 + 1 
69 PE(34:1) 718.6>577.52 + 1 
70 PE(34:2) 716.5>575.50 + 1 
71 PE(34:3) 714.5>573.49 + 1 
72 PE(36:1) 746.6>605.55 + 1 
73 PE(36:2) 744.6>603.53 + 1 
74 PE(36:3) 742.6>601.52 + 1 
75 PE(36:4) 740.5>599.50 + 1 
76 PE(36:5) 738.5>597.49 + 1 
77 PE(38:0) 776.6>635.60 + 1 
78 PE(38:1) 774.6>633.58 + 1 
79 PE(38:2) 772.6>631.57 + 1 
80 PE(38:3) 770.6>629.55 + 1 
81 PE(38:4) 768.6>627.53 + 1 
82 PE(38:5)* 766.6>625.52 + 1 
83 PE(38:7) 762.5>621.49 + 1 
84 PE(40:0) 804.7>663.63 + 1 
85 PE(40:4) 796.6>655.57 + 1 
86 PE(40:5) 794.6>653.55 + 1 
87 PE(40:6) 792.6>651.53 + 1 
88 PE(40:7) 790.6>649.52 + 1 
89 PE(40:8) 788.5>647.50 + 1 
90 PE(42:0) 832.7>691.66 + 1 
91 PE(42:1) 830.7>689.64 + 1 
92 PE(44:0) 860.7>719.69 + 1 
93 LPG(14:1) 455.3>283.14 + 1 
94 LPG(16:0) 485.3>313.19 + 1 
95 LPG(16:1) 483.3>311.17 + 1 
96 LPG(18:1) 511.3>339.20 + 1 
97 LPG(18:2) 509.3>337.19 + 1 
98 LPI(16:0) 571.3>241.01 - 1 
99 LPI(18:0) 599.3>241.01 - 1 
100 LPI(18:1) 597.3>241.01 - 1 
101 LPI(18:2) 595.3>241.01 - 1 
102 LPI(20:4) 619.3>241.01 - 1 
103 LPI(22:6) 643.3>241.01 - 1 
104 PI(34:1) 835.6>241.01 - 1 
105 PI(34:2) 833.5>241.01 - 1 
106 PI(36:1) 863.6>241.01 - 1 
107 PI(36:2) 861.6>241.01 - 1 
108 PI(36:3) 859.6>241.01 - 1 
109 PI(36:4) 857.5>241.01 - 1 
110 PI(36:5) 855.5>241.01 - 1 
111 PI(38:4) 885.6>241.01 - 1 
112 PI(38:5) 883.6>241.01 - 1 
113 PI(38:6) 881.5>241.01 - 1 
114 PI(40:6) 909.6>241.01 - 1 
115 LPS(16:0) 498.3>313.26 + 1 
116 LPS(18:0) 526.3>341.29 + 1 
117 LPS(18:1) 524.3>339.28 + 1 
118 LPS(18:2) 522.3>337.26 + 1 
119 LPS(20:4) 546.3>361.26 + 1 
120 LPS(22:6) 570.3>385.26 + 1 
121 PS(34:1) 762.6>577.51 + 1 
122 PS(36:1) 790.6>605.54 + 1 
123 PS(36:2) 788.6>603.52 + 1 
124 PS(36:4) 784.5>599.49 + 1 
125 PS(36:5) 782.5>597.48 + 1 
126 PS(36:6) 780.5>595.46 + 1 
127 PS(38:3) 814.6>629.54 + 1 
128 PS(38:4) 812.6>627.52 + 1 
129 PS(38:6) 808.5>623.49 + 1 
130 PS(38:8) 804.5>619.46 + 1 
131 PS(40:4) 840.6>655.56 + 1 
132 PS(40:5) 838.6>653.54 + 1 
133 PS(40:6) 836.6>651.52 + 1 
134 PS(40:7) 834.6>649.51 + 1 
135 SM(32:1) 675.6>184.10 + 1 
136 SM(32:2) 673.6>184.10 + 1 
137 SM(34:2) 701.6>184.10 + 1 
138 SM(36:1) 731.6>184.10 + 1 
139 SM(36:2) 729.6>184.10 + 1 
140 SM(36:3) 727.6>184.10 + 1 
141 SM(36:4) 725.6>184.10 + 1 
142 SM(38:2)* 757.6>184.10 + 1 
143 SM(38:6) 749.6>184.10 + 1 
144 SM(40:2)* 785.7>184.10 + 1 
145 sphingosine-1-phosphate (17:0) IS 366.3>250.4 + 1 
*0.5 µl sample injection volume 
 
  
Table S5: Mass transitions for identified significantly changed lipid mediators. The target 
ion shows the multiple reaction monitoring (MRM) transitions, the ionization polarity (IP) 
shows the ionization mode of the ESI source and the internal standard (IS) column assigns the 
number of the internal standard to the lipid mediators with which they were evaluated. The 
internal standard is marked in bold letters. 
no. compound  target ion  IP IS 
1 9,10-DiHOME 9,10-dihydroxy-octadecenoic acid 313,2>201,2 - 1 
2 14-HDoHE 14-hydroxy-docosahexaenoic acid 343,2>205,2 - 1 
3 19-HETE 19-hydroxyeicosatetraenoic acid 319,2>275,2 - 1 
4 AA arachidonic acid 303,2>303,2 - 1 
5 cholic acid†  407.25>407.25 - 1 
6 DCA† deoxycholic acid 391.30>391.30 - 1 
7 DHA docosahexaenoic acid 327,2>283,2 - 1 
8 EPA eicosapentaenoic acid 301,2>257,2 - 1 
9 GLCA† glycolithocholic acid 432.30>432.30 - 1 
10 Lyso-PAF lyso-platelet activating factor 482,3>184,1 - 1 
11 OEA oleoylethanolamine 326,2>62,1 + 1 
12 TCDCA† taurochenodeoxycholic acid 498.40>498.40 - 1 
13 TDCA† taurodeoxycholic acid  498.40>498.40 - 1 
14 UDCA† ursodeoxycholic acid 391.30>391.30 - 1 
15 S1P (17:0) IS sphingosine-1-phosphate (17:0) IS  366.3>250.4 + 1 
†illustrated in heatmap of primary metabolites 
 
  
Table 6: Mass transitions for sphingosine-1-phosphate and sphingosine. The target ion 
shows the multiple reaction monitoring (MRM) transitions, the ionization polarity (IP) shows 
the ionization mode of the ESI source and the internal standard (IS) column assigns the number 
of the internal standard to the compounds with which they were evaluated. The internal 
standard is marked in bold letters. 
no. compound target ion IP IS 
1 sphingosine-1-phosphate† 380.3>264.4 + 1 
2 sphingosine† 300.4>282.4 + 1 
3 sphingosine-1-phosphate (17:0) IS  366.3>250.4 + 1 
†illustrated in heatmap of phospholipids II 
 
Supplementary Table 7. Average concentration of cytokines in serum. Mice underwent sham or CLP surgery, 24 h later 31 cytokines and 
chemokines were assessed in serum. Data are expressed as mean ± SEM (pg/ml). The following groups were studied WT sham (n = 5), Xid sham 
(n = 5), WT-CLP (n = 10), Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8), Xid-CLP + ibrutinib (n = 6). 
 WT Sham Xid Sham WT CLP Xid CLP WT CLP + ibrutinib Xid CLP + ibrutinib 
 Mean SEM +/- Mean SEM +/- Mean SEM +/- Mean SEM +/- Mean SEM +/- Mean SEM +/- 
BCA-1/CXCL13 7034.2 3097.9 8937.8 2330.0 83810.3 4310.6 77435.3 2269.3 85285.5 3220.6 80840.9 1375.5 
CTACK/CCL27 1872.3 202.1 2327.4 398.1 3886.4 339.4 8395.2 1781.0 7661.8 1191.3 7369.2 1032.9 
ENA-78/CXCL5 1980.0 772.6 2831.5 987.5 45770.7 5248.7 8462.4 969.7 11727.6 2524.8 7210.7 982.8 
Eotaxin/CCL11 420.6 151.2 733.3 171.2 6869.6 356.5 1952.5 224.5 2690.1 465.2 1907.8 179.3 
Eotaxin-2/CCL24 13102.7 4999.2 18708.2 3000.5 56736.3 5714.4 25735.7 2079.7 11983.1 1876.6 29652.0 3562.5 
Fractalkine/CXCL1 264.5 9.1 279.7 17.5 1181.9 109.7 322.8 12.2 457.7 47.5 352.9 20.4 
GM-CSF 5.4 0.8 5.4 0.7 346.2 58.6 7.5 1.1 14.7 3.2 7.7 0.7 
I-309/CCL1 45.6 4.9 58.4 14.0 198.7 66.5 799.7 190.5 80.1 15.6 11691.8 9593.7 
IFN-γ 133.8 11.1 155.5 17.5 134.0 16.2 102.3 15.1 98.1 28.8 191.6 14.4 
IL-1β 680.0 57.0 706.3 72.6 1536.3 184.7 674.6 31.4 611.0 43.8 768.9 28.0 
IL-2 11.7 2.6 15.9 4.0 38.3 7.8 102.6 25.8 72.8 15.4 57.4 18.7 
IL-6 45.5 4.8 52.6 6.7 524272.8 43243.2 6380.9 1557.2 29367.0 18095.0 4296.7 1827.7 
IL-4 74.7 3.6 87.5 8.0 65.2 3.9 76.0 8.0 52.3 9.2 92.0 3.5 
IL-10 1296.5 84.4 1677.4 159.6 23882.5 2465.0 2077.0 370.9 3485.3 947.8 2252.3 362.6 
IL-16 978.4 68.9 1048.3 87.4 2836.1 207.4 1313.4 86.9 1814.6 200.3 1462.5 95.6 
IP-10/CXClL10 4561.3 205.3 4994.1 536.0 4837.9 327.2 4547.3 583.3 4036.2 420.8 5182.1 157.5 
I-TAC/CXCL11 4666.7 272.0 5570.1 490.2 3217.0 291.5 3372.9 340.1 2991.7 826.7 5569.5 376.0 
KC/CXCL1 298.0 24.0 337.9 24.5 158693.9 35967.2 9014.0 1570.5 16952.6 6344.1 8912.3 2432.5 
MCP-1/CCL2 515.8 36.3 601.9 59.7 262035.2 117148.0 9660.5 3217.7 10558.8 3887.3 3100.1 531.8 
MCP-5/CCL12 24.0 4.9 31.6 4.5 5348.5 785.1 935.7 129.2 1020.6 157.1 758.3 70.1 
MDC/CCL22 190.9 41.0 210.3 35.3 1869.7 235.7 494.0 48.3 515.9 36.1 717.8 69.6 
MIP-1α/CCL3 27.5 2.1 34.0 3.7 4994.4 1664.0 175.4 56.9 81.7 24.5 56.1 2.2 
MIP1-β/CCL4 123.9 6.9 141.1 12.9 51791.1 19413.9 1445.3 372.8 2859.4 1022.9 509.2 68.5 
MIP-3α/CCL20 38.8 3.4 41.7 4.4 893.8 117.3 691.2 157.2 549.9 176.4 1134.8 163.6 
MIP-3β/CCL19 2285.8 104.5 2520.6 204.6 3622.2 350.3 3830.6 351.0 2933.2 242.3 4925.1 465.9 
Rantes/CCL5 28.8 5.4 33.4 5.9 2647.5 421.4 80.0 10.3 487.9 148.7 110.0 24.3 
SCYB16/CXCL16 601.1 133.4 748.4 91.0 4588.5 467.1 2250.7 317.4 2440.4 447.1 1851.1 266.6 
SDF-1α/CXCL12 929.5 197.3 1263.0 218.9 447.7 63.0 1612.0 177.7 1113.3 341.6 2304.9 389.7 
TARC/CCL17 115.6 16.7 146.8 21.6 3293.6 376.2 2269.2 441.2 755.4 114.8 5268.3 1862.4 
TNF-α 311.2 16.7 310.6 28.0 471.7 42.9 205.1 16.5 208.5 38.7 330.8 27.1 
